8 20 symptom free 2 NEJM Clinical Practice fluticasone 1 2 fluticasone IgE 100U/ml 1819 Bostock 1 A Mycobacterium Toxoplasma
|
|
- もえり ながおか
- 5 years ago
- Views:
Transcription
1 The Lancet, vol 378, Dec.17/24/31,2011 Alexander N Greiner USA Peter W Hellings, Guiseppina Rotiroti Glenis K Scadding The Lancet, Dec. 17/24/31, The Lancet 3 fluticasone: 1 P montelukast /20
2 8 20 symptom free 2 NEJM Clinical Practice fluticasone 1 2 fluticasone IgE 100U/ml 1819 Bostock 1 A Mycobacterium Toxoplasma IgE 2,5,6,7,11,13,16, /20
3 mast cell IgE CD4+T montelukast( ) benefit NNT NNH number needed to harm NNH Benefit azelastine 0.16(1 / ) / (omalizumab) montelukast 0.07 montelukast ( / ) omalizmab IgE cromolyn 2 Nasal filter nasal filter nasal filter 3/20
4 nasal douching normal saline nasal douching ml 1 3 nasal douching 1 neurotrophin NGF (nerve growth factor) BDNF (brain-derived neurotrophic factor: ) The Lancet Allergic rhinitis 53 4/20
5 The Lancet, vol378,dec.17/24/31, fluticasone IgE 13. 2,5,6,7,11,13,16, IgE 100U/ml 15. A Mycobacterium Toxoplasma IgE IgE entopy 27. neurotrophin 28. neurotrophin NGF,BDNF 29. 5/20
6 OAS 34. IgE 35. IgE nasal filter montelukast( ) 45. montelukast montelukast 48. NNT montelukast /20
7 The Lancet, vol378,dec.17/24/31,2011 Alexander N Greiner USA Peter W Hellings, Guiseppina Rotiroti Glenis K Scadding 10 QOL IgE IgE meta-analysis ( ) 1 P disease course 5 1 Introduction rhinoviral infection odds ratio /20
8 The ARIA(Allergic Rhinitis and its Impact on Asthma)guideline QOL fluticasone disease course Bostock 4 1 ISAAC (International Study of Asthma and Allergies in Childhood) Phase Phase 2 Phase 3 5 8/20
9 Phase median 6.9 % median 13.6 % 5 Phase median 14.6% aero-allergens odds ratio CI odds ratio CI IgE no older siblings 9/20
10 4 6 IgE 100IU/ml A Mycobacterium Toxoplasma gondii endotoxin lipopolysaccharides hygiene hypothesis occupational rhinitis a. IgE IgE grain elevator : b. IgE anhydrides c. IgE di-isocyanate 5. odds ratio 10/20
11 Eustachian tube QOL QOL 20 QOL 11/20
12 ARIA guideline dendritic cell T peptide T lymphopoietin T helper2 (Th2) CD4 T IL4, 5, 10, 13 IL4 B IgE class switch IgE mast cell IgE early nasal response TNF leukotrienec4 prostaglandin D2 CD4+T CD4+T IL5 IL5 eosinopoiesis IgE IgE B IgE IgE entopy eosinophilia IgE eosinophilia Entopy 12/20
13 IgE RAST IgE entopy rhinopathy Eosinophilia neurotrophins NGF(nerve growth factor) BDNF(brain-derived neurotrophic factor: ) pan-neurotrophin receptor p75 tyrosine kinase A B BDNF NGF BDNF BDNF NGF T regulatory T lymphocytes T homeostasis CD4+CD25+ T T 1 Tr1 IL10 Th2 Th2 T Tr1 IL10 TGF transforming growth factor 8. nasal obstruction (congestion) 1 2 hyposmia odds ratio /20
14 nasal-ocular reflex birch oral allergy syndrome OAS OAS 2/3 1/3 Churg-Strauss syndrome Wegener s granulomatosis, Sarcoidosis IgE skin prick test IgE RAST: radioallergosorbent test 15 RAST RAST IgE house dust mite 14/20
15 cystic fibrosis, primary ciliary dyskinesia, Non-allergic rhinitis with eosinophilia : entopy(local nasal IgE) Churg-Strauss syndrome, Wegener s granulomatosis, Sarcoidosis, Relapsing polychondritis, SLE, nasal valve dysfunction, HRT Acromegaly NSAID 10 a. house dust mite nasal filter placebo-control study 15/20
16 (saline douching) rhinosinusitis b. QOL ARIA 3 meta-analysis fluticasone: secondary care Chromones( ) /20
17 Decongestants 10 rhinitis medicamentosa on-demand therapy montelukast Churg-Strauss syndrome Decongestants pseudoephedrine Van Cauwenberge IgE monoclonal antibody omalizumab: c. Benefit azelastine 0.16(1 / ) / montelukast /20
18 (omalizumab) NNT number needed to treat / / montelukast 14.3 omalizumab Harm / / montelukast 0.01 omaolizumab NNH (number needed to harm 1 ) / 22 2 / monteolukast 167 omalizumab d. IgE douching /20
19 decongestant 1 e. birch open control group CI CI n189, 511observations CI % /20
20 local oral changes f. nasal-valve dysfunction /20
0.02ml IgE RAST MAST CAP 2
( ) 1 0.02ml IgE RAST MAST CAP 2 3 1963 30 4 1986 20 39 IgE 30% 1988 54.7% IgE 47.6% 1990 892 IgE 27% 12% 1995 2379 1995 8 15 1996 1 12 2335 98.5% 2335 24 61 47 44.0 1 1) 2335 613 26.3% 2 5 613 43.4 44.2
More informationスライド 1
QOL 1 Goldberg, JCO 22:23-30, 2004 N9741: Oxaliplatin in First Line (US) IR 200 mg/m 2 OX 85 mg/m 2 every 3 weeks Efficacy IFL FOLFOX4 > IFL IROX FOLFOX4 IROX OS TTP RR 15.0 mo 6.9 mo 31 % P=0.0001 P=0.0014
More information免疫Ⅱ
100 100 100 1990 127 DNA DNA DNA DNA hybridization DNA RNA DNA DNA 128 12 µδγαε 129 300 1,200 500 50012 4 24,000 1,20024,000 2.910 7 10 8 rejection major histocompatibility complex MHC MHC MHC 130 MHC
More information05-d m-4.03
Feb. THE JAPANESE JOURNAL OF ANTIBIOTICS 58 1 51(51) ABPA(M) 1 ABPM ITCZ 2 ABPA ITCZ 3 ABPA ABPM ABPM 52(52) THE JAPANESE JOURNAL OF ANTIBIOTICS 58 1 Feb. 9 2004 3 6 4 Feb. THE JAPANESE JOURNAL OF ANTIBIOTICS
More information2
27 年 度 精 神 保 健 福 祉 基 礎 研 修 会 1 2 350 300 303 323 250 200 150 100 50 218 218 173 136 119 212 204 258 228 247 237 147 142 152 137 137 127 128 134 107 91 86 81 11 14 17 20 3 4 350 300 250 200 150 4.7 3.8
More information第79回_プログラム.indd
Regulation of ghrelin signaling by a leptin-induced gene, negative regulatory element-binding protein, in the hypothalamic neurons. Phase I clinical trial using peptide vaccine for human vascular endothelial
More information19 8 1970 20 10 4 1
19 8 1970 20 10 4 1 IgE 1960 % 1970 20%, 1990 40% 1998 70% 20 IgE 21 90% IgE IgE (%) 70 60 50 40 30 20 10 0 1970 1975 1980 1985 1990 1995 2000 2005 1. 2005 10 2 30 IgE 2. 3 1. B IgE T IgE IgE IgE 2 T IgE
More information01.浅野.ppt
2010 14 23 1 15 2010 the 74 th Annual Scientific Meeting of American College of Rheumatology November 7 11, 2010 at Georgia World Congress Center, Atlanta, GA, USA 2284 SSc 142 Plenary Session: 3 Concurrent
More informationKey words : Adverse reactions, Egg allergy, IgG antibody, Mills allergy, FAST
Key words : Adverse reactions, Egg allergy, IgG antibody, Mills allergy, FAST 13) Danaeus, A., Johansson, S. G. O., Foucard, T. & Ohman, S.: Clinical and immunogical aspects of food allergy in childhood.
More informationSBP hospitalist network.key
1 Treatment and Prophylaxis of Spontaneous Bacterial Peritonitis (1); (2), (3). (1) (2) (3) :, :, 2 Clinical Question 1 72...,.,,.,... 3. CT..,. 4? SBP? SBP. 5 Clinical Question SBP? SBP,? 6 SBP (Spontaneous
More information喘息について\(公健協会宛02-5作成\)
Q & A Q & A 1.? 20 2. 1) 2) 3) 4) 5) 6) 7) 1) 2) 3) 4) 5) 6) 7) 8) 9) 3. NHK ( ) 4 10 1 200mg ( ) ( 1 ) 4. ( ) ( ) 5. ( ) ( ) 6. β 2 ( ) 7. ( ) 1 8. 1. 2. 3. 4. 5. 6. 7. 8. 9. 2 5 7 1. 1 10 1) 2) 3) 30
More information好酸球性副鼻腔炎:診断ガイドライン(JESREC Study)
118 728 2015 : : JESREC Study Japanese Epidemiological Survey of Refractory Eosinophilic Chronic Rhinosinusitis Study : JESREC Study CT NSAIDs CT : JESREC Study JESREC Study 118 729 ph CTMRI Caldwell Luc
More informationDISTRIBUTION OF NEUROPEPTIDES IN THE INFERIOR NASAL TURBINATE MUCOSA OF PATIENTS WITH ALLERGIC RHINITIS KAZUHIRO YAMAMOTO. M.D. Department of Otolaryngology, School of Medicine, Kitasato University, Sagamihara
More information16 9 Paula TFC BMI PSL hydroxysteroid dehydrogenase (11 -HSD) modulator ( prereceptor mod
Glucocorticoid-Induced Bone Disease (Clinical Practice) NEJM, July 7, 2011 Robert S. Weinstein, M.D. NEJM July 7 2011 Clinical Practice Glucocorticoid-Induced Bone Disease Arcansas Robert S. Weinstein,
More information<2003年分東京医科歯科大学産科婦人科学教室業績>
1.Obayashi S, Aso T, Sato J, Hamasaki H, Azuma H: Intimal hyperplasia in human uterine arteries accompanied by impaired synergism between prostaglandin I2 and nitric oxide. British Journal of Pharmacology
More informationニュースレター10-1.indd
The Japanese Society of Immunotoxicology 101192005 aaaa 12 2005172021 1-1-1 Tel. 03-5841-8205 / Dr. R.H. Pieters () "Immunotoxicology of therapeutics associated with allergy and autoimmunity" 2005 In
More informationVENTANA ALK D5F3 Rabbit Monoclonal Antibody OptiView ALK D5F3
VENTANA ALK D5F3 Rabbit Monoclonal Antibody OptiView ALK D5F3 2 OptiView ALK D5F3 11 10 79.3%31% 18% 80 85NSCLC 40% 1,2 1 1018 ALK ALK 2 ALK 3 5% ALK EML4 EML4-ALK Coild-Coil ALK ALK 3,4,5 2 6 EGFR 50%
More information研究成果報告書(基金分)
(1) 種類 程度 肥満細胞数の測定と組織でのサ RT-PCR FACS () (1) NMU-/- IgE NMU IgE -/-NMU -/-B IgE NMU -/-B6 IgE NMU NMU CTLMC BMMC IgE NMU CTLMC 13 1. Hayakawa J, Mizukawa Y, Kurata M, Shiohara T: A syringotropic variant
More information第11回 化学物質の環境リスクに関する国際シンポジウム 発表資料
平成 20 年度 化学物質の環境リスクに関する国際シンポジウム 2008.12.15 免疫 アレルギー系の制御機構 Regulatory Mechanisms of the Immune System and Allergic Diseases 東京大学医科学研究所ヒト疾患モデル研究センター岩倉洋一郎 Center for Experimental Medicine, Institute of Medical
More information2001 2003 2005 2006 2007 2008
2001 2003 2005 2006 2007 2008 60 etc. http://nosmoke.hp.infoseek.co.jp/yuugaibussitu.htm http://nosmoke.hp.infoseek.co.jp/yuugaibussitu.htm 23.5% 2.8% 2.8% 3.4% 30.3% 9.9% 11.5% 15.8% AAN 65
More information3 6 6 8 5 5 0 4 3 4 4 0,000 3 ID ID ID 4 7 9 :5 4 5 60-8048 NACOS TEL: 075-45-366 FAX: 075-45-366 E-mail: jiao@nacos.com 3. Power Point PC 0 5. Power Point PC 7 3 3. 3 5 PC PC PC Windows Power Point USB
More information【知事入れ版】270804_鳥取県人口ビジョン素案
7 6 5 4 3 2 1 65 1564 14 192 193 194 195 196 197 198 199 2 21 22 23 24 1.65 1,4 1.6 1,2 1.55 1, 1.45 6 1.5 8 1.4 4 1.35 1.3 2 27 28 29 21 211 212 213 214 6 5 4 3 2 1 213 218 223 228 233 238 243 248 253
More information第14〜15回 T細胞を介する免疫系.pptx
MBL CD8 CD4 8.1 8.2 5.20 8.3 8.4 8.5 8.6 8.7 8.8 8.9 8.10 8.18 B7 CD28 CD28 B7 CD28 8.13 2.22 NK Toll(TLR) LBP! LPS dsrna ssrna TLR1/2/6! TLR4 TLR5 TLR3 TLR7/9 CD14! JNK/p38! MyD88! IRAK! TRAF! NFκB! TNF-α
More informationIPAG診断・治療ハンドブック 日本語版
2005 2005 1 IPAG International Primary Care Airways GroupIPAG IPAG STAFF IPAG Coordinator: L Grouse, S Prete, A Wright Editors: L Grouse, S DeWeerdt IPAG EXPERT PANEL AND AUTHORS O van Schayck, Chair A
More information平成15 年度 大気汚染と花粉症の相互作用に関する調査研究(疫学研究)研究報告書
13 13 2 MEDLINE 2001 13 (1) 2002 1) 1996 1997 56,108 50,086 89.3% 5.2% 2002 2) 1998 6 9,471 4,035 42.6% 17,301 8,527 8,774 16.2% 17.3% 10 60 11.7% 19.8% 60 Okuda 2003 3) 10,920 12 3,370 390 28 2001 4 7
More information2
2 3 4 5 6 7 8 9 1 2 3 4 5 10 11 12 1 2 1 2 1 2 13 14 3 17 15 1 2 3 D Usefulness of Tc-99m MIBI SPECT in predicting multidrug resistance gene expression level in non-small cell lung cancer a preliminary
More information日本化学療法学会雑誌第65巻第4号
Mycoplasma pneumoniae M. pneumoniae M. pneumoniae M. pneumoniae M. pneumoniae M. pneumoniae Key words Mycoplasma pneumoniae Mycoplasma pneumoniae M. pneumoniae I M. pneumoniae M. pneumoniae M. pneumoniae
More information14UNAIDS HIV 39% i 9 ii9iii UNAIDS x.9x.9x1= ?? UNAIDS % 77%8% 44.7x.77x.8x1=
DeCEMBER, 17 No.34 HIV 169-73 1-1-1-13TEL 3-5937-4413:3 19:3 FAX 3-5937-443E-mail info@janpplus.jp http://janpplus.jp/!9-9-9!... 1-3 POSITIVE HIV/AIDS UNAIDS!... 4-5 JaNP+HIV Cafe Bar an opportunity...
More informationJHN Journal Club 手稲渓仁会病院
JHOSPITALIST network GUIDE-IT trial; The Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure multicentre randomised clinical trial 20171010 1 70 (EF 30%), (PCI), (HbA1c
More informationMV X 5 6 Common Terminology Criteria for Adverse Events Grade 1 Grade Gy 16 QOL QOL 5 6 7, 8 9, VOL.3 NO
乳がん患者の放射線皮膚炎に対するスキンケアの指導の実際 がん放射線療法看護認定看護師とがん放射線治療に携わる看護師との比較 Educating practice of skin care for radiodermatitis of breast cancer patients: Comparison of the nurses with certified nurse in radiation therapy
More information31, 21% 24, 17% 8, 5% 23, 16% 24, 16% 91, 62% 19, 13% 39, 27% 33, 23% 73 48 57 51 31 1 9 13.0% 7.4% 5.3% 12.5% 17.1% 13.2% 17.9% 4.5% 36.4% 56.5% 40.7% 36.8% 50.0% 67.1% 56.3% 65.8% 75.0% 26.0% 37.0%
More information37 27.0% 26 19.0% 74 54.0% 9 6.4% 13 9.2% 28 19.9% 26 18.4% 37 26.2%. 24 17.0% 99 69 75 59 39 1 6 4.5% 1.4% 7.7% 2.9% 25.0% 17.9% 20.8% 50.0% 41.7% 47.0% 51.4% 54.3% 61.5% 57.1% 55.6% 42.4% 50.0% 58.3%
More information3 DI 29 7 1 5 6 575 11 751, 13 1,1,25 6 1,251,5 2 1,51,75 1,752, 1 2,2,25 2,252,5 2,53, 3,3,5 3,5 5 1 15 2 25 3 5 6 575 12 751, 21 1,1,25 27 1,251,5 9 1,51,75 1,752, 1 2,2,25 2 2,252,5 2,53, 2 3,3,5
More information% 32.3 DI DI
2011 7 9 28.1 41.4 30.5 35.8 31.9% 32.3 DI 18.2 2.4 8.1 3.5 DI 9.4 32.2 0.0 25.9 2008 1 3 2 3 34.8 65.2 46.753.8 1 2 8.82.9 43.1 10 3 DI 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25
More information2 DI 28 7 1 37 28 4 18 27 11 21 5 2 26 4 5 1 15 2 25 3 35 4 17 7 5 48 76 31 47 17 2 92 12 2 2 4 6 8 1 12 1 2 4 1 12 13 18 19 3 42 57 57 1 2 3 4 5 6 1 1 1 3 4 4 5 5 5.5 1 1.5 2 2.5 3 3.5 4 4.5 5
More information2 E.coli 30 85 32 1 G 1 NEJM 2 250 2 / 3 200 2 / 3 638.4 500 1 / 3 1547.1 3 7 3 3 513 2 500 2 / 1g/ / 7 750 / / 5 TMP80mg, SMX400mg 2 2 / 14 10 14 GM+
Clinical Practice Uncomplicated Urinary Tract Infection NEJM March15,2012 Thomas M. Hooton, M.D. H24.3 NEJM March15, 2012 Clinical Practice UTI UTI E.coli 2010 IDSA Infectious Diseases Society of America
More informationuntitled
19 CSPOR CRC/2009.8.8-9 2009 8 8 ( ) - CSPOR CRC SEMINAR- twatanab@oncoloplan.com http://www.oncoloplan.com - Toru Watanabe MD - 2 Phase I: Dose Finding trial Phase II : Efficacy and Safety trial Phase
More information野岩鉄道の旅
29th 5:13 5:34 5:56 6:00 6:12 6:20 6:21 6:25 6:29 6:31 6:34 6:38 6:40 6:45 6:52 6:56 7:01 7:07 7:11 7:32 7:34 7:50 7:58 8:03 8:17 8:36 8:44 5:50 5:54 6:15 6:38 6:39 6:51 6:59 6:59 7:03 7:08 7:08 7:11 7:15
More informationuntitled
29 10 1 2011 12 JRSJ Vol. 29 No. 10 2 Dec., 2011 29 10 3 2011 12 JRSJ Vol. 29 No. 10 4 Dec., 2011 29 10 5 2011 12 JRSJ Vol. 29 No. 10 6 Dec., 2011 29 10 7 2011 12 JRSJ Vol. 29 No. 10 8 Dec., 2011 29 10
More informationAbbreviation: AD; atopic dermatitis, BA; bronchial asthma, DA; drug allergy, FA; food allergy, BAST; radioallergosolvent test, s. c; subcutaneous
Abbreviation: AD; atopic dermatitis, BA; bronchial asthma, DA; drug allergy, FA; food allergy, BAST; radioallergosolvent test, s. c; subcutaneous Fig. I Total serum IgE and IgE RAST score of egg white
More informationWHO Library Cataloguing in Publication Data 2003, Wilkinson,Richard Marmot,Michael Social determinants of health SDH The social gradient Stress Early life Social exclusion Work Unemployment Social support
More information第20回愛知県作業療法学会.indd
20 The 20 th Aichi Occupational Therapy Congress 24 513 20 2012 513 20 TEL0587513333FAX0587513300 INDEX 1 2 3 4 5 6 7 8 11 15 25 38 39 40 20 10 30 11 20 11 30 12 30 10 30 11 20 11 30 12 30 14 00 15 30
More informationuntitled
-- -- -3- % % % 6% % % 9 66 95 96 35 9 6 6 9 9 5 77 6 6 5 3 9 5 9 9 55 6 5 9 5 59 () 3 5 6 7 5 7 5 5 6 6 7 77 69 39 3 6 3 7 % % % 6% % % (: ) 6 65 79 7 3 36 33 9 9 5 6 7 3 5 3 -- 3 5 6 76 7 77 3 9 6 5
More informationuntitled
NO. 2007 10 10 34 10 10 0570-058-669 http://www.i-nouryoku.com/index.html (40 ) () 1 NO. 2007 10 10 2.2 2.2 130 70 20 80 30 () () 9 10 () 78 8 9 () 2 NO. 2007 10 10 4 7 3 NO. 2007 10 10 40 20 50 2 4 NO.
More information08-g-”O−}„j‹ê-4.02
200( 96 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 58 2 Apr. 585 1 17 MIC 1. (Transtracheal aspiration: TTA) TTA TTA TTA 1400 TTA (diffuse panbronchiolitis, DPB) 1) erythromycin(em) EM 12.5% 87.5% 2,3) EM EM
More information/ / A/ B 16/17 COPD 18mcg COPD COPD COPD 1
11 1 -------------------- 19 205.117/205.128 14/15 205.126A/205.126B 16/17 COPD 18mcg COPD 11.1 11.1.1 COPD 100 19 205.227 COPD 1 FEV1.0 %FEV1.0 70% 1 FEV1.0 / FVC 70% 2 1 200 3 40 COPD 1 10mg ACE 1 1
More information第26回日本サルコイドーシス/肉芽腫性疾患学会総会議事報告
26 2005 2005 2006 2006 2005 2005 Prof. Gianfranco Rizzato D. Geraint James W. Jones Williams Om P. Sharma 28 28 26 26 10WASOG 2007WASOG-DLD Diffuse Lung Disease Conference2007 10 WASOG2007 109 2007, 27
More information眼科領域アレルギー性疾患に対する診断と治療
57 4 213 220 2014 1 2 3 1. allergic conjunctival disorders ACD 1 allergic conjunctivitis AC 2 seasonal allergic conjunctivitis SAC perennial allergic conjunctivitis PAC atopic keratoconjunctivitis AKC
More informationuntitled
1988 2000 2002 2004 2006 2008 IFN Lamivudine Adefovir Entecavir 1 Total number 560 Sex (male/female) 424/136 Age (years)* 38 (15-68) Duration of treatment (weeks)* 26 (1-592) Follow-up time (years) 75(05-21
More informationuntitled
The Sense of Burden of Mother with Severely Disabled Children at Home and the Related Factors Noriko Kuno Keiko Yamaguchi Chieko Morita Key Words sense of burden, severely disabled children, mother,, Luescher
More information1 4 1 13 1 4 6 7 2012 7 27 12 50 13 40 1 7 27 13 40 14 30 1 7 28 13 20 14 10 1 Prevalence and characteristics of undiagnosed bipolar disorders in patients with a major depressive episode Charles L. Bowden
More information< A F BF8A69955C8DEC90AC8D5291CC506C CB3967B292E786C7378>
輸 / 販売元 110-0008 東京都台東区池之端 2-9-1 エッジ ビル 本社 179-0073 東京都練 区 柄 3-14-17 E-mail info@digital-biology.co.jp URL http://www.digital-biology.co.jp 製造元 BioLegend 社 /BioLegend URL http:// http://www.biolegend.com/
More information17. (1) 18. (1) 19. (1) 20. (1) 21. (1) (3) 22. (1) (3) 23. (1) (3) (1) (3) 25. (1) (3) 26. (1) 27. (1) (3) 28. (1) 29. (1) 2
1. (1) 2. 2 (1) 4. (1) 5. (1) 6. (1) 7. (1) 8. (1) 9. (1) 10. (1) 11. (1) 12. (1) 13. (1) 14. (1) 15. (1) (3) 16. (1) 1 17. (1) 18. (1) 19. (1) 20. (1) 21. (1) (3) 22. (1) (3) 23. (1) (3) 24. 1 (1) (3)
More information橡'98寺尾班報告書.PDF
(OHSS) interleukin-8 (IL -8) 33 histamine prostaglandin angiotensin 8 IL-8 OHSS 1 IL-8 23 Wistar rat pregnant mare serum gonadotropin 10 unit 48 human chorionic gonadotropin(hcg) 10 unit IL-8 0.2, 2.0,
More informationみさき_1
2 3 4 5 6 7 1F 2F 8 9 10 11 17 18 19 20 21 22 23 24 31 25 26 27 28 29 30 8 1 2 3 4 5 6 7 6 8 7 16 7 8 9 10 11 12 14 15 13 17 23 Vol.41 8 6 20 11 7 15 7 23 7 7 7 16 23 23 8 13 18:00 22:00 722
More informationVol..3 2010 2 10 2
1 Vol..3 2010 2 10 2 Vol..3 2010 2 10 3 Vol..3 2010 2 10 4 Vol..3 2010 2 10 5 Vol..3 2010 2 10 6 Vol..3 2010 2 10 7 Vol..3 2010 2 10 8 Vol..3 2010 2 10 9 Vol..3 2010 2 10 10 Vol..3 2010 2 10 11 Vol..3
More information